uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
Clin Ctr Serbia, Cardiol Clin, Belgrade, Serbia.;Univ Belgrade, Sch Med, Belgrade 11001, Serbia..
Univ Belgrade, Sch Med, Belgrade 11001, Serbia..
Heart Ctr Leipzig, Dept Electrophysiol, Leipzig, Germany..
Hosp Univ Virgen de la Arrixaca, IMIB Arrixaca, Dept Cardiol, Murcia, Spain..
Show others and affiliations
2016 (English)In: Current Medicinal Chemistry, ISSN 0929-8673, E-ISSN 1875-533X, Vol. 23, no 19, 2070-2083 p.Article, review/survey (Refereed) Published
Abstract [en]

The kidney has numerous complex interactions with the heart, including shared risk factors (e.g., hypertension, dyslipidemia, etc.) and mutual amplification of morbidity and mortality. Both cardiovascular diseases and chronic kidney disease (CKD) may cause various alterations in cardiovascular system, metabolic homeostasis and autonomic nervous system that may facilitate the occurrence of cardiac arrhythmias. Also, pre-existent or incident cardiac arrhythmias such as atrial fibrillation (AF) may accelerate the progression of CKD. Patients with CKD may experience various cardiac rhythm disturbances including sudden cardiac death. Contemporary management of cardiac arrhythmias includes the use of antiarrhythmic drugs (AADs), catheter ablation and cardiac implantable electronic devices (CIEDs). Importantly, AADs are not used only as the principal treatment strategy, but also as an adjunct therapy in combination with CIEDs, to facilitate their effects or to minimize inappropriate device activation in selected patients. Along with their principal antiarrhythmic effect, AADs may also induce cardiac arrhythmias and the risk for such proarrhythmic effect(s) is particularly increased in patients with reduced left ventricular systolic function or in the setting of electrolyte imbalance. Moreover, CKD itself can induce profound alterations in the pharmacokinetics and pharmacodynamics of many drugs including AADs, thus facilitating the drug accumulation and increased exposure. Hence, the use of AADs in patients with CKD may be challenging. In this review article, we provide an overview of the characteristics of arrhythmogenesis in patients with CKD with special emphasis on the complexity of pharmacokinetics and risk for proarrhythmias when using AADs in patients with cardiac arrhythmias and CKD.

Place, publisher, year, edition, pages
2016. Vol. 23, no 19, 2070-2083 p.
Keyword [en]
Cardiac arrhythmias, chronic kidney disease, drug dosing, antiarrhythmic drugs, risk factors, atrial fibrillation, ventricular arrhythmias, sudden cardiac death
National Category
Cardiac and Cardiovascular Systems Medicinal Chemistry
URN: urn:nbn:se:uu:diva-303468DOI: 10.2174/0929867323666160309114246ISI: 000380786400012PubMedID: 26955880OAI: oai:DiVA.org:uu-303468DiVA: diva2:971957
Available from: 2016-09-19 Created: 2016-09-19 Last updated: 2016-09-19Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Blomström-Lundqvist, Carina
By organisation
In the same journal
Current Medicinal Chemistry
Cardiac and Cardiovascular SystemsMedicinal Chemistry

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 19 hits
ReferencesLink to record
Permanent link

Direct link